阿斯利康是全球领先的跨国制药企业，位列《财富》杂志全球500强第252位（07年公布最新排名），2006年公司全球营业额高达265亿美元。阿斯利康总部位于英国伦敦，全球员工65,000名。业务范围覆盖全球100多个国家和地区。阿斯利康在全球有27个生产基地。

阿斯利康大力投资研发，每个工作日投入高达1600万美元。在多个国家（美、英、法、瑞典、加拿大、日本、中国、印度）设有16个研发机构，科研人员12,000名。前后共有9位诺贝尔奖获得者曾和阿斯利康密切合作从事药物研究创新。

阿斯利康在6大治疗领域为患者提供富于创新，卓有成效的医药产品，包括消化、心血管、肿瘤、中枢神经、麻醉和呼吸等，其中许多产品居于世界领先地位。2006年阿斯利康开始进入抗菌素领域,开发研制新一代的抗菌素以治疗对现有抗菌素高度耐药的重症感染病人.

阿斯利康中国区总部位于上海，在中国大陆设有25个办事处，现有近3000名员工，分布在生产、销售、临床研究和新产品开发等领域。阿斯利康坚持“立足中国，造福中国”的理念，长远规划，长线投资。阿斯利康在无锡已投资一亿七千万美元，建设了阿斯利康在亚洲最大的生产基地，投入生产六年来，运行良好，得到江苏省政府高度评价。

AstraZeneca is one of the world’s leading pharmaceutical companies with sales reaching $26.5 billion in 2006 and ranks No. 252 on the Fortune 500 list in 2007. AstraZeneca is headquartered in London, and has 65,000 employees worldwide. It has 27 manufacturing sites in 19 countries. Its business covers over 100 countries and regions throughout the world.

AstraZeneca has been investing heavily in R&D, up to $16 million investment each working day.It has established 16 R&D centers in many countries including the U.S., the U.K., France, Sweden, Canada, Japan, China and India. Approximately 12,000 employees work in those R&D organizations. In addition, nine Nobel Prize-winning scientists have collaborated with AstraZeneca in innovative medicine research.

AstraZeneca provides innovative, effective medicines to fight diseases in six important areas of medical need: cardiovascular, cancer, neuroscience, gastrointestinal, anesthetic, and respiratory. Most of its products are world- leading in their respective areas. In 2006, AstraZeneca entered the antibiotic area and developed novel therapy for severely infected patients having high drug resistance.

AstraZeneca China has its headquarters in Shanghai, with 25 branch offices in major cities across China’s mainland. It has nearly 3,000 employees working in manufacturing, sales, clinical research and new product development. AstraZeneca is committed to being "In China, For China" with long-term planning and investment. In 2001, the company established its largest manufacturing site in Asia with a total investment of $170 million in Wuxi, China.